secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmatrix, Inc. (PULM)
CIK:        0001574235
Form:       8-K
Filed at:   2024-05-15T23:59:59+00:00
Accession:  0001493152-24-019558
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmatrix Phase 1 data for inhaled DHE (PUR3100) published: rapid absorption, better tolerability vs IV DHE
--------------------------------------------------------------------------------

- All PUR3100 doses showed mean Cmax above 1000 pg/mL efficacy threshold; Tmax 5 min vs 5.5 min for IV DHE.
- Lower incidence of nausea (21% vs 86%), vomiting (0% vs 29%), and headache (16% vs 57%) compared to IV DHE.
- Data published in Headache: The Journal of Head and Face Pain; FDA allowed Phase 2 study to proceed.
- Company seeking financing or partnership to advance PUR3100 into Phase 2 for acute migraine.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224019558/0001493152-24-019558-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1574235/000149315224019558/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-019558

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer